FDA Clears IND for EB06 Vitiligo Trial, Opening U.S. Enrollment
EDSA has more than doubled off its 52-week low of $0.72.
Summary
The FDA cleared Edesa's IND for a Phase 2 study of EB06 in vitiligo, letting the company add U.S. sites and begin enrolling up to 80 adults next quarter. Recruitment is already running in Canada, and the double-blind trial uses F-VASI at Week 28 as its primary endpoint. This is a real de-risking step for the program, but the payoff is distant: topline data aren't expected until Q4 2027. The timing matters because the Q3 10-Q carried a going concern warning and management said resources won't fund operations through fiscal 2026, so the $25 million August offering at $5.50 a share is what keeps this trial moving. Watch for U.S. site activation and enrollment pace next quarter.
Updates
· SEC 8-K — The Phase 2 study will enroll up to 80 adults with moderate-to-severe nonsegmental vitiligo, randomized 1:1 to EB06 or placebo every two weeks through Week 22.
At the time of this announcement, EDSA was trading at $2.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.8M. The 52-week trading range was $0.72 to $20.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.